Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,080 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,814 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,434 | $164.01 | $235,190.34 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,434 shares sold at prices ranging from $163.66 to $164.36 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 8,478 | $163.23 | $1,383,863.94 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,619 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 8,478 shares sold at prices ranging from $162.66 to $163.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 787 | $161.73 | $127,281.51 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,097 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 787 shares sold at prices ranging from $161.65 to $162.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000022 · wk-form4_1775680879.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,520 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,073 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,533 | $144.11 | $653,250.63 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 4,533 shares sold at prices ranging from $143.80 to $144.72 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,537 | $143.42 | $650,696.54 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,718 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,537 shares sold at prices ranging from $142.80 to $143.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,629 | $142.17 | $231,594.93 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,255 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,629 shares sold at prices ranging from $141.80 to $142.74 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000020 · wk-form4_1774037117.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,960 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,332 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,128 | $147.54 | $313,965.12 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,128 shares sold at prices ranging from $147.15 to $148.04 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F6 · balance_after: The Reporting Person no longer has a reportable beneficial interest in the securities owned by the William Lewis Family Legacy Trust, which were included in the Reporting Person's prior ownership reports. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,899 | $146.66 | $571,827.34 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,313 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 3,899 shares sold at prices ranging from $146.09 to $147.06 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,589 | $145.27 | $376,104.03 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,212 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 2,589 shares sold at prices ranging from $144.99 to $145.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,083 | $144.23 | $300,431.09 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,801 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 2,083 shares sold at prices ranging from $143.84 to $144.70 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000018 · wk-form4_1772745408.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,400 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,591 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,030 | $153.38 | $157,981.40 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 1,030 shares sold at prices ranging from $153.00 to $153.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,377 | $151.92 | $361,113.84 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,215 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,377 shares sold at prices ranging from $151.56 to $152.43 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,413 | $151.12 | $515,772.56 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,592 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 3,413 shares sold at prices ranging from $150.54 to $151.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,891 | $150.10 | $283,839.10 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,005 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,891 shares sold at prices ranging from $149.53 to $150.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,988 | $149.17 | $296,549.96 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,896 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,988 shares sold at prices ranging from $148.51 to $149.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:34 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000015 · wk-form4_1771882447.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,850 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,840 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,287 | $148.83 | $191,544.21 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,287 shares sold at prices ranging from $148.62 to $149.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,221 | $148.02 | $1,068,852.42 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,472 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 7,221 shares sold at prices ranging from $147.61 to $148.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,888 | $147.17 | $719,366.96 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,693 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,888 shares sold at prices ranging from $146.61 to $147.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,009 | $156.34 | $470,427.06 |
DisclosureSEC source: 0001402051-26-000011 · wk-form4_1770239840.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,882 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,280 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,109 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 254 | $160.70 | $40,817.80 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,891 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 254 shares sold at prices ranging from $160.58 to $160.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,229 | $159.85 | $356,305.65 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,145 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,229 shares sold at prices ranging from $159.55 to $160.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,967 | $158.99 | $948,693.33 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,374 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 5,967 shares sold at prices ranging from $158.55 to $159.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,243 | $158.37 | $196,853.91 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,341 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,243 shares sold at prices ranging from $157.54 to $158.53 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,006 | $156.80 | $157,740.80 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,584 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,006 shares sold at prices ranging from $156.53 to $157.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 13 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,720 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,368 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.